What does the fixed combination of valsartan and sacubitrilu patients with heart failure - the results of the study PARADIGM-HF
2017
Abstract
The combination of valsartan sacubitril represents a new class of drugs called ARNI (angiotensin receptor - neprilysin inhibitor). The mechanism of action is the simultaneous suppression of the renin-angiotenzin-aldosterone system (via blocade of type 1 angiotensin II receptor, valsartan) and increased plasma natriuretic peptides inhibits its degradation (neutral endopeptidase inhibiting sacubitril).
In view of the positive results in clinical studies (PARADIGM-HF), it seems that this effect is consistent across wide range of subgroups analyzed. For these reasons, treatment sacubitril/valsartan was included in the therapeutic algorithm of the chronic heart failure.